These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 21718737)

  • 1. Immunogenicity assay validation for an HIV vaccine trial: high IFNγ+/IL-2+ CD8+ T cells background in healthy Thais.
    Sirivichayakul S; Thantiworasit P; Chatkulkawin P; Buranapraditkun S; Munier ML; Kelleher AD; Ruxrungtham K
    Vaccine; 2011 Aug; 29(35):6002-7. PubMed ID: 21718737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
    Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
    AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an alternative intracellular cytokine staining assay for HIV/AIDS clinical studies.
    Chen H; Reichman R; Keefer M; McDermott MP; Jin X
    J Virol Methods; 2005 Feb; 123(2):131-40. PubMed ID: 15620394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 8. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced CD8+ T lymphocytes of rhesus monkeys recognize variant forms of an HIV epitope but do not mediate optimal functional activity.
    Hulot SL; Cale EM; Korber BT; Letvin NL
    J Immunol; 2011 May; 186(10):5663-74. PubMed ID: 21490161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Support for the RV144 HIV vaccine trial.
    AIDS Vaccine Advocacy Coalition
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
    Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE;
    J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 18. Outstanding questions on HIV vaccine trial.
    Jefferys R; Harrington M
    Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
    [No Abstract]   [Full Text] [Related]  

  • 19. New research in HIV immunity points way for vaccine.
    Rees J
    Immunotherapy; 2013 May; 5(5):445-6. PubMed ID: 23638739
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.
    Horton H; Thomas EP; Stucky JA; Frank I; Moodie Z; Huang Y; Chiu YL; McElrath MJ; De Rosa SC
    J Immunol Methods; 2007 May; 323(1):39-54. PubMed ID: 17451739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.